Retrophin Announces Proposed Public Offering of Common Stock
Retrophin, Inc. (Nasdaq: RTRX) announced its intention to conduct an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The exact terms and size of the offering remain uncertain. Jefferies, Barclays, and BofA Securities are serving as joint book-running managers for this offering. Shares will be offered under a shelf registration statement effective since September 4, 2018. A preliminary prospectus will be filed with the SEC.
- Retrophin aims to raise capital through an underwritten public offering, which may be used to support its development projects.
- The offering could lead to shareholder dilution if additional shares are sold.
- Market conditions may affect the completion and terms of the offering.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. All of the shares are being offered by Retrophin. In addition, Retrophin intends to grant the underwriters for the offering a 30-day option to purchase up to an additional
Jefferies, Barclays and BofA Securities are acting as the joint book-running managers for the offering.
The shares of common stock described above are being offered by Retrophin pursuant to a shelf registration statement filed by Retrophin with the Securities and Exchange Commission (SEC) that became automatically effective on September 4, 2018. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 888-603-5847 or by email at barclaysprospectus@broadridge.com; or from BofA Securities, Attention Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 28255, by telephone at 800-299-1322 or by email at dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Retrophin, Inc.
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are partially supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “plan,” “believe,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Retrophin’s expectations with respect to the completion, timing and size of the proposed public offering and granting the underwriters a 30-day option to purchase additional shares. For such statements, Retrophin claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Retrophin’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Retrophin’s filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. These forward-looking statements represent Retrophin’s judgment as of the time of this release. Retrophin disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
Retrophin, Inc.
888-969-7879
IR@retrophin.com
FAQ
What is the purpose of Retrophin's public offering announced on June 8, 2020?
How many shares is Retrophin planning to offer in this public offering?
Who is managing Retrophin's public offering?
What potential impacts could the offering have on RTRX shareholders?
